Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453

Phase 1 Completed 57 enrolled Bial - Portela C S.A.

RandomizedParallel-groupDouble-blindTreatment

The purpose of this study is to assess the tolerability of BIA 5-453 after six multiple rising dose regimens of BIA 5-453.

Evaluation	Drug	Modality	Dose	Route
Subject	BIA 5-453	Unknown	25 mg	Oral
Subject	BIA 5-453	Unknown	50 mg	Oral
Subject	BIA 5-453	Unknown	100 mg	Oral
Subject	BIA 5-453	Unknown	200 mg	Oral
Subject	BIA 5-453	Unknown	400 mg	Oral
Subject	BIA 5-453	Unknown	600 mg	Oral